Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Canine parainfluenza virus antigen refers to the immunogenic proteins of the canine parainfluenza virus (CPIV), also known as parainfluenza virus 5 (PIV5) or Orthorubulavirus mammalis. CPIV is a highly contagious, enveloped, single-stranded RNA virus belonging to the Paramyxoviridae family. It is a primary viral pathogen responsible for canine infectious respiratory disease complex (CIRDC), commonly known as kennel cough. The key antigenic targets on the virus include the hemagglutinin-neuraminidase (HN) glycoprotein, which mediates viral attachment to host epithelial cells, and the fusion (F) protein, which facilitates viral entry into the host cell.
Vaccines containing attenuated or inactivated CPIV antigens are widely used in veterinary medicine to stimulate active immunity, inducing the production of neutralizing antibodies and cell-mediated immune responses. While these vaccines do not provide sterilizing immunity, they significantly reduce the severity of clinical symptoms, viral replication, and shedding in infected dogs. In addition to vaccines, CPIV antigens are the primary targets for diagnostic assays, such as lateral flow rapid tests and ELISAs, which are used to detect active infections in veterinary clinics.
Active immunization to stimulate the host immune system to produce neutralizing antibodies and cell-mediated immune responses against canine parainfluenza virus, thereby preventing or reducing viral replication, shedding, and clinical severity of canine infectious respiratory disease complex.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Canine parainfluenza virus antigen (CPIV-Ag).